Tags

Type your tag names separated by a space and hit enter

Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3.
Int J Cancer 2005; 113(6):991-7IJ

Abstract

The role of nutrient-related genetic susceptibility factors for pre-cancerous lesions is gaining attention. We conducted a study to examine associations between polymorphisms in folate pathway coenzymes (methylenetetrahydrofolate reductase [MTHFR] and methionine synthase [MS]) and cervical intraepithelial neoplasia (CIN) 2 or 3 in a population exposed to folic acid by the food fortification program in the United States. Status of MTHFR and MS and circulating concentrations of folate, vitamins B12, A, E, C and total carotene were ascertained in 170 Caucasian and 266 African-American women positive for high-risk human papilloma virus (HR-HPV). Polymorphism status was determined using polymerase chain reaction assays. Micronutrient concentrations were measured using radiobinding assays, high performance liquid chromatography or spectrophotometry. Presence/absence of CIN 2 or 3 was determined on the basis of histology results and the association with risk factors was examined using multivariable analyses. Eighty women had CIN 2 or 3 lesions and they were compared to 356 women who had CIN 1, ASCUS or normal cytology. We found that women polymorphic for MTHFR were less likely to have CIN 2 or 3 (odds ratio [OR] = 0.43, 95% confidence interval [CI] = 0.23-0.79). No associations were seen with MS polymorphism alone (OR = 0.72, 95% CI = 0.43-1.21); however, women polymorphic for both MTHFR and MS were less likely to have CIN 2 or 3 (OR = 0.21, 95% CI = 0.08-0.62). We conclude that these polymorphisms in the folate metabolic pathway were associated with a lower likelihood of CIN 2 or 3 in a population exposed to adequate amounts of folate from exposure to food fortification with folic acid.

Authors+Show Affiliations

Department of Epidemiology of the University of Alabama at Birmingham, Birmingham, AL, USA. ohenao@uab.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15514969

Citation

Henao, Olga L., et al. "Women With Polymorphisms of Methylenetetrahydrofolate Reductase (MTHFR) and Methionine Synthase (MS) Are Less Likely to Have Cervical Intraepithelial Neoplasia (CIN) 2 or 3." International Journal of Cancer, vol. 113, no. 6, 2005, pp. 991-7.
Henao OL, Piyathilake CJ, Waterbor JW, et al. Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. Int J Cancer. 2005;113(6):991-7.
Henao, O. L., Piyathilake, C. J., Waterbor, J. W., Funkhouser, E., Johanning, G. L., Heimburger, D. C., & Partridge, E. E. (2005). Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. International Journal of Cancer, 113(6), pp. 991-7.
Henao OL, et al. Women With Polymorphisms of Methylenetetrahydrofolate Reductase (MTHFR) and Methionine Synthase (MS) Are Less Likely to Have Cervical Intraepithelial Neoplasia (CIN) 2 or 3. Int J Cancer. 2005 Mar 1;113(6):991-7. PubMed PMID: 15514969.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. AU - Henao,Olga L, AU - Piyathilake,Chandrika J, AU - Waterbor,John W, AU - Funkhouser,Ellen, AU - Johanning,Gary L, AU - Heimburger,Douglas C, AU - Partridge,Edward E, PY - 2004/10/30/pubmed PY - 2005/3/8/medline PY - 2004/10/30/entrez SP - 991 EP - 7 JF - International journal of cancer JO - Int. J. Cancer VL - 113 IS - 6 N2 - The role of nutrient-related genetic susceptibility factors for pre-cancerous lesions is gaining attention. We conducted a study to examine associations between polymorphisms in folate pathway coenzymes (methylenetetrahydrofolate reductase [MTHFR] and methionine synthase [MS]) and cervical intraepithelial neoplasia (CIN) 2 or 3 in a population exposed to folic acid by the food fortification program in the United States. Status of MTHFR and MS and circulating concentrations of folate, vitamins B12, A, E, C and total carotene were ascertained in 170 Caucasian and 266 African-American women positive for high-risk human papilloma virus (HR-HPV). Polymorphism status was determined using polymerase chain reaction assays. Micronutrient concentrations were measured using radiobinding assays, high performance liquid chromatography or spectrophotometry. Presence/absence of CIN 2 or 3 was determined on the basis of histology results and the association with risk factors was examined using multivariable analyses. Eighty women had CIN 2 or 3 lesions and they were compared to 356 women who had CIN 1, ASCUS or normal cytology. We found that women polymorphic for MTHFR were less likely to have CIN 2 or 3 (odds ratio [OR] = 0.43, 95% confidence interval [CI] = 0.23-0.79). No associations were seen with MS polymorphism alone (OR = 0.72, 95% CI = 0.43-1.21); however, women polymorphic for both MTHFR and MS were less likely to have CIN 2 or 3 (OR = 0.21, 95% CI = 0.08-0.62). We conclude that these polymorphisms in the folate metabolic pathway were associated with a lower likelihood of CIN 2 or 3 in a population exposed to adequate amounts of folate from exposure to food fortification with folic acid. SN - 0020-7136 UR - https://www.unboundmedicine.com/medline/citation/15514969/Women_with_polymorphisms_of_methylenetetrahydrofolate_reductase__MTHFR__and_methionine_synthase__MS__are_less_likely_to_have_cervical_intraepithelial_neoplasia__CIN__2_or_3_ L2 - https://doi.org/10.1002/ijc.20695 DB - PRIME DP - Unbound Medicine ER -